EP1183013A2 - Melt granulation - Google Patents

Melt granulation

Info

Publication number
EP1183013A2
EP1183013A2 EP00931886A EP00931886A EP1183013A2 EP 1183013 A2 EP1183013 A2 EP 1183013A2 EP 00931886 A EP00931886 A EP 00931886A EP 00931886 A EP00931886 A EP 00931886A EP 1183013 A2 EP1183013 A2 EP 1183013A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical formulation
formulation according
clarithromycin
prepared
granulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931886A
Other languages
German (de)
French (fr)
Inventor
Darja; Fercej Temeljotov
Judita Sirca
Milojka; Mohar
Mateja Salobir
Andrej; Golmajer
Marko Opresnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Publication of EP1183013A2 publication Critical patent/EP1183013A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention belongs to the field of pharmaceutical technology and discloses melt granulation.
  • the present invention discloses a simple one-step process for coating clarithromycin or derivatives thereof by means of melt granulation in order to effectively cover their bitterness, as well as a new, patient- friendly oral pharmaceutical formulation suitable also for diabetics, which at the same time also enables variations in the rate and site of the release of the active component.
  • Clarithromycin is a slightly basic, practically water-insoluble, acid-sensitive macrolide antibiotic with a very bitter taste that remains in the mouth for several hours after taking a therapeutical dose.
  • the commercially available oral suspension with clarithromycin contains a considerable amount of sugar (which does not eliminate the bitter aftertaste), but it still has a relatively unpleasant taste. Moreover, the technology of the preparation thereof is a multistep one and hence expensive.
  • the present invention arises from the need to prepare an oral suspension with clarithromycin or derivatives thereof, which will be tasty, effective and obtainable by means of a one-step process.
  • Clarithromycin is a semi-synthetic antibiotic obtained by methylation of erythromycin in the lactone position C6. The synthesis is described in US 4,331,803 and US 4,672,109. It is active against gram-positive bacteria and, due to the broad spectrum of antimicrobial activity, it is used clinically. On the market it is available in the form of coated tablets, suspensions and prolonged-release tablets.
  • JP 85/163823 discloses an oral medicament with clarithromycin, citric acid increasing the abso ⁇ tion of antibiotic in the alimentary tract, disintegrants, excipients and lubricants.
  • EP 0277042 discloses an oral pharmaceutical formulation (also with macrolides) with an improved taste and having a coating of particular polymers (especially polyvinyl acetal diethylaminoacetate - AEA), soluble in gastric juice and with a mean particle diameter under 60 ⁇ m.
  • US 4,808,411 discloses a pharmaceutical formulation with erythromycin or its derivatives and a carbomer, possibly in the form of ion-complex particles coated with a polymer, which can be suspended in a liquid carrier.
  • JP 01-308,223 discloses the preparation of film-coated microgranules of a sustained- release medicament containing AEA and water in addition to clarithromycin.
  • EP 0302370 and WO 90/08537 disclose improved oral pharmaceutical formulations (oil solution, suspension, emulsion) of erythromycin and derivatives to be filled into soft gelatine capsules with N-methyl-pyrrolidone.
  • EP-B-0420992 discloses a process for the production of an oral pharmaceutical formulation (also with macrolides) with a masked taste, which comprises spraying a medicament suspension into a cold water solution of AEA.
  • JP 02-279,622 discloses oral medicaments with AEA, prepared by a fine granulation of a medicament (clarithromycin) dispersed in a melted oil base (cacao butter), followed by suspending the fine particles in a water solution of AEA and spray-drying the suspension.
  • AEA a fine granulation of a medicament (clarithromycin) dispersed in a melted oil base (cacao butter), followed by suspending the fine particles in a water solution of AEA and spray-drying the suspension.
  • US 5,017,383 discloses a method for the production of a finely coated pharmaceutical formulation, which comprises mixing frozen particles of a liquid medium with a medicament (also with macrolides) and a coating in the form of a fine powder adhering onto the surface of the particles.
  • JP 05-255,075 discloses melt granulation of macrolides, wherein the coating consists of polymers soluble in stomach (particularly Eudragit E), which are dispersed in compounds with a low melting point.
  • the final granulation is performed by spraying.
  • the final preparation of a dry syrup is accomplished by mixing granules with sugar and hydroxypropyl methyl cellulose (HPMC).
  • US 5,599,556 and US 5,609,909 disclose the masking of the taste of encapsulated clarithromycin particles with prolamine coatings prior to the preparation of a suspension.
  • WO 96/34628 discloses an oral pharmaceutical formulation (also with macrolides) for masking the taste (particularly a dry syrup), which contains a medicament with an unpleasant taste, a higher polymer soluble in stomach (particularly AEA and Eudragit E) and a monoglyceride with a low melting point (particularly glyceryl monostearate) in the stable crystal form ⁇ (transformed from the metastable form ⁇ by additional shaking at increased temperature), and a method of masking the taste.
  • WO 97/16174 discloses a process of water granulation of a macrolide antibiotic with a carbomer (acrylic polymer).
  • US 5,705,190 discloses a controlled-release solid oral pharmaceutical formulation (also of clarithromycin) containing a medicament weakly soluble in water, a water- soluble alginate salt, a complex salt of alginic acid with a metal cation and an organic carboxylic acid facilitating the dissolution of the medicament.
  • US 5,707,646 discloses a pharmaceutical formulation (also with macrolides) for oral use (particularly a dry syrup) containing a medicament with an unpleasant taste, a functional polymer (particularly AEA or/and Eudragit E) in a substance with a melting point of 40-120 °C, a sugar alcohol (e.g. sorbitol) and a basic oxide (particularly MgO).
  • a pharmaceutical formulation also with macrolides
  • a dry syrup containing a medicament with an unpleasant taste
  • a functional polymer particularly AEA or/and Eudragit E
  • a sugar alcohol e.g. sorbitol
  • a basic oxide particularly MgO
  • WO 98/46239 discloses a delayed-release pharmaceutical formulation containing an erythromycin derivative and a hydrophilic water-soluble polymer, which in oral use has an improved taste profile and fewer gastrointestinal side effects in comparison with the common form.
  • the preparation technology includes, inter alia, wet granulation, drying, sieving and milling processes.
  • the aim of the present invention is a new oral pharmaceutical formulation with clarithromycin or derivatives thereof.
  • clarithromycin which may be present alone or in a homogeneuos mixture with conventional adjuvants, with a lipid film- forming substance having a low melting point (below 100 °C).
  • the granulate was prepared in the melt in a mixer-granulator, thus in one step and in one vessel without the use of any solvents. From the granulate various conventional final pharmaceutical formulations such as suspensions in concentrations of 125 mg/5 ml and 250 mg/5 ml, tablets or capsules can be prepared.
  • the base for coating can be clarithromycin itself or its mixture with excipients such as lactose, calcium carbonate, sodium hydrogen phosphate, NaCl, citric acid, PEG or stomach-insoluble polymers such as Eudragit L or S (1:1 or 1 :2 copolymer of methacrylic acid and MMA), microcrystalline cellulose etc.
  • excipients such as lactose, calcium carbonate, sodium hydrogen phosphate, NaCl, citric acid, PEG or stomach-insoluble polymers such as Eudragit L or S (1:1 or 1 :2 copolymer of methacrylic acid and MMA), microcrystalline cellulose etc.
  • the weight ratio between clarithromycin and these excipients amounts from 5: 1 to 1 : 1.2
  • lipid film-forming substance almost insoluble in water there can be used a higher fatty alcohol, preferably stearyl, cetostearyl or cetyl alcohol or a suitable acid such as stearic acid or a physical mixture or an ester of several such components e.g. stearyl stearate.
  • a higher fatty alcohol preferably stearyl, cetostearyl or cetyl alcohol or a suitable acid such as stearic acid or a physical mixture or an ester of several such components e.g. stearyl stearate.
  • the weight ratio between clarithromycin and these excipients amounts from 2: 1 to 1 :2.
  • the melt granulation is performed in such a way that a mixture of clarithromycin (possibly with addition of adjuvants) and of the lipid for coating is heated in a granulator under mixing to the melting point of the lipid component and then the obtained granulate is slowly cooled.
  • viscosity enhancers and stabilizers such as xanthan gum, guar gum, silica gel, magnesium aluminium silicate etc.
  • sugar or sweetening agents such as aspartame, sodium saccharinate or erythritol, caramel, vanilla or fruit flavours and colouring agents can also be added.
  • all the cited additives for the preparation of suspensions cannot cover the bitterness of clarithromycin by themselves.
  • the pharmaceutical formulation of the present invention can be improved by using polyols instead of sugar, which makes it also suitable for diabetics.
  • polyols instead of sugar
  • e.g. xylitol and mannitol and their combinations with maltitol, maltol and sorbitol can be used.
  • the present pharmaceutical formulation represents the only oral suspension with clarithromycin, which is not based on sugar (saccharose).
  • Fatty alcohols such as stearyl alcohol possess, in proportion to their concentration, a delaying effect on the release of the active component from the pharmaceutical formulation. This property can be used for controlling the clarithromycin release rate and an oral suspension with delayed action can be prepared.
  • a gastroresistant layer onto the granulate base from the melt, the site of clarithromycin release in the alimentary tract can be affected.
  • Polymers forming a gastroresistant coating such as shellac, cellulose acetate phthalate, HPMC phthalate, ethylcellulose latex, polymethacrylates etc. can be used therefor.
  • the preparation of the granulate was identical to that of Examples 1 or 2. Additionally, a gastroresistant coating was applied; for 200 mg of pellet cores the following dispersion was prepared:
  • the preparation of the granulate was identical to the one of Examples 1 or 2. Additionally, a gastroresistant coating was applied; for 500 mg of pellet cores the following water dispersion was prepared: Eudragit L 30 D-55 48.612 mg triethyl citrate 0.893 mg talc 0.495 mg water 332.143 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Deposition Of Substances Of Which Semiconductor Devices Are Composed (AREA)
  • Glanulating (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

The present invention discloses a simple one-step process of coating by means of melt granulation for effective masking of bitterness, and a new, patient-friendly oral pharmaceutical formulation suitable also for diabetics, which at the same time also enables variations in the rate and site of the release of the active component.

Description

MELT GRANULATION
Technical Field
International Patent Classification: A 61 J 3/02, C 07 G 11/00
The present invention belongs to the field of pharmaceutical technology and discloses melt granulation.
More specifically, the present invention discloses a simple one-step process for coating clarithromycin or derivatives thereof by means of melt granulation in order to effectively cover their bitterness, as well as a new, patient- friendly oral pharmaceutical formulation suitable also for diabetics, which at the same time also enables variations in the rate and site of the release of the active component.
Technical Problem
Clarithromycin is a slightly basic, practically water-insoluble, acid-sensitive macrolide antibiotic with a very bitter taste that remains in the mouth for several hours after taking a therapeutical dose.
Since some groups of patients (children, the elderly, patients with swallowing disorders) cannot take solid medical preparations (tablets, capsules) and the same groups are also very sensitive to the (un)acceptable taste of a medical preparation, there existed a need to find an effective technological solution to cover or mask the bitter taste of clarithromycin or its derivatives, i.e. a need to prepare a suspension for oral use, which will be both patient-friendly and therapeutically effective.
The commercially available oral suspension with clarithromycin contains a considerable amount of sugar (which does not eliminate the bitter aftertaste), but it still has a relatively unpleasant taste. Moreover, the technology of the preparation thereof is a multistep one and hence expensive.
Thus, the present invention arises from the need to prepare an oral suspension with clarithromycin or derivatives thereof, which will be tasty, effective and obtainable by means of a one-step process.
Prior Art
Clarithromycin is a semi-synthetic antibiotic obtained by methylation of erythromycin in the lactone position C6. The synthesis is described in US 4,331,803 and US 4,672,109. It is active against gram-positive bacteria and, due to the broad spectrum of antimicrobial activity, it is used clinically. On the market it is available in the form of coated tablets, suspensions and prolonged-release tablets.
Different oral pharmaceutical formulations with clarithromycin are also described in the following patents:
JP 85/163823 discloses an oral medicament with clarithromycin, citric acid increasing the absoφtion of antibiotic in the alimentary tract, disintegrants, excipients and lubricants.
EP 0277042 discloses an oral pharmaceutical formulation (also with macrolides) with an improved taste and having a coating of particular polymers (especially polyvinyl acetal diethylaminoacetate - AEA), soluble in gastric juice and with a mean particle diameter under 60 μm.
US 4,808,411 discloses a pharmaceutical formulation with erythromycin or its derivatives and a carbomer, possibly in the form of ion-complex particles coated with a polymer, which can be suspended in a liquid carrier. JP 01-308,223 discloses the preparation of film-coated microgranules of a sustained- release medicament containing AEA and water in addition to clarithromycin.
EP 0302370 and WO 90/08537 disclose improved oral pharmaceutical formulations (oil solution, suspension, emulsion) of erythromycin and derivatives to be filled into soft gelatine capsules with N-methyl-pyrrolidone.
EP-B-0420992 discloses a process for the production of an oral pharmaceutical formulation (also with macrolides) with a masked taste, which comprises spraying a medicament suspension into a cold water solution of AEA.
JP 02-279,622 discloses oral medicaments with AEA, prepared by a fine granulation of a medicament (clarithromycin) dispersed in a melted oil base (cacao butter), followed by suspending the fine particles in a water solution of AEA and spray-drying the suspension.
US 5,017,383 discloses a method for the production of a finely coated pharmaceutical formulation, which comprises mixing frozen particles of a liquid medium with a medicament (also with macrolides) and a coating in the form of a fine powder adhering onto the surface of the particles.
JP 05-255,075 discloses melt granulation of macrolides, wherein the coating consists of polymers soluble in stomach (particularly Eudragit E), which are dispersed in compounds with a low melting point. The final granulation is performed by spraying. The final preparation of a dry syrup is accomplished by mixing granules with sugar and hydroxypropyl methyl cellulose (HPMC).
US 5,599,556 and US 5,609,909 disclose the masking of the taste of encapsulated clarithromycin particles with prolamine coatings prior to the preparation of a suspension. WO 96/34628 discloses an oral pharmaceutical formulation (also with macrolides) for masking the taste (particularly a dry syrup), which contains a medicament with an unpleasant taste, a higher polymer soluble in stomach (particularly AEA and Eudragit E) and a monoglyceride with a low melting point (particularly glyceryl monostearate) in the stable crystal form β (transformed from the metastable form α by additional shaking at increased temperature), and a method of masking the taste.
WO 97/16174 discloses a process of water granulation of a macrolide antibiotic with a carbomer (acrylic polymer).
US 5,705,190 discloses a controlled-release solid oral pharmaceutical formulation (also of clarithromycin) containing a medicament weakly soluble in water, a water- soluble alginate salt, a complex salt of alginic acid with a metal cation and an organic carboxylic acid facilitating the dissolution of the medicament.
US 5,707,646 discloses a pharmaceutical formulation (also with macrolides) for oral use (particularly a dry syrup) containing a medicament with an unpleasant taste, a functional polymer (particularly AEA or/and Eudragit E) in a substance with a melting point of 40-120 °C, a sugar alcohol (e.g. sorbitol) and a basic oxide (particularly MgO).
WO 98/46239 discloses a delayed-release pharmaceutical formulation containing an erythromycin derivative and a hydrophilic water-soluble polymer, which in oral use has an improved taste profile and fewer gastrointestinal side effects in comparison with the common form. The preparation technology includes, inter alia, wet granulation, drying, sieving and milling processes.
Thus, numerous publications exist in the patent and other literature in that field disclosing the composition and preparation of various pharmaceutical formulations with clarithromycin. However, we have not found any literature source disclosing such a simple process for the preparation of a clarithromycin suspension having such a simple composition, a good smell and taste as well as a possibility of upgrading for diabetics. Additionally, it also enables the controlling of the rate and the site of the release of the active component.
Technical Solution
The aim of the present invention is a new oral pharmaceutical formulation with clarithromycin or derivatives thereof. Surprisingly, the bitter taste of clarithromycin has been very successfully masked by coating clarithromycin, which may be present alone or in a homogeneuos mixture with conventional adjuvants, with a lipid film- forming substance having a low melting point (below 100 °C). The granulate was prepared in the melt in a mixer-granulator, thus in one step and in one vessel without the use of any solvents. From the granulate various conventional final pharmaceutical formulations such as suspensions in concentrations of 125 mg/5 ml and 250 mg/5 ml, tablets or capsules can be prepared.
The base for coating can be clarithromycin itself or its mixture with excipients such as lactose, calcium carbonate, sodium hydrogen phosphate, NaCl, citric acid, PEG or stomach-insoluble polymers such as Eudragit L or S (1:1 or 1 :2 copolymer of methacrylic acid and MMA), microcrystalline cellulose etc. The weight ratio between clarithromycin and these excipients amounts from 5: 1 to 1 : 1.2
As the lipid film-forming substance almost insoluble in water there can be used a higher fatty alcohol, preferably stearyl, cetostearyl or cetyl alcohol or a suitable acid such as stearic acid or a physical mixture or an ester of several such components e.g. stearyl stearate. The weight ratio between clarithromycin and these excipients amounts from 2: 1 to 1 :2.
The melt granulation is performed in such a way that a mixture of clarithromycin (possibly with addition of adjuvants) and of the lipid for coating is heated in a granulator under mixing to the melting point of the lipid component and then the obtained granulate is slowly cooled. For the final preparation of the granulate for suspensions there are also added viscosity enhancers and stabilizers such as xanthan gum, guar gum, silica gel, magnesium aluminium silicate etc. For a better taste, smell and appearance, sugar or sweetening agents such as aspartame, sodium saccharinate or erythritol, caramel, vanilla or fruit flavours and colouring agents can also be added. However, all the cited additives for the preparation of suspensions cannot cover the bitterness of clarithromycin by themselves.
The pharmaceutical formulation of the present invention can be improved by using polyols instead of sugar, which makes it also suitable for diabetics. For this purpose e.g. xylitol and mannitol and their combinations with maltitol, maltol and sorbitol can be used. Thus, the present pharmaceutical formulation represents the only oral suspension with clarithromycin, which is not based on sugar (saccharose).
Fatty alcohols such as stearyl alcohol possess, in proportion to their concentration, a delaying effect on the release of the active component from the pharmaceutical formulation. This property can be used for controlling the clarithromycin release rate and an oral suspension with delayed action can be prepared.
Additionally or optionally, by applying a gastroresistant layer onto the granulate base from the melt, the site of clarithromycin release in the alimentary tract can be affected. Polymers forming a gastroresistant coating such as shellac, cellulose acetate phthalate, HPMC phthalate, ethylcellulose latex, polymethacrylates etc. can be used therefor.
The present invention is illustrated but in no way limited by the following Examples:
Example 1
In a mixer-granulator 2 kg of clarithromycin and 2 kg of stearyl alcohol were homogeneously mixed. During mixing it was heated to the melting point and a chopper was switched on. Then it was cooled under constant mixing. Spherical granules/pellets were formed. Dry additives were added thereto.
Dry additives per vial or per 5.00 g of clarithromycin-stearyl granulate (pellets):
Na2HP04 1.000 g
NaCl 1.000 g aspartame 0.100 g aerosil 0.400 g vanilla flavour 0.070 g ammonium glycirhizinate 0.140 g xylitol 60.690 g methyl hydroxybenzoate 0.260 g titanium dioxide 0.050 g quinoline yellow colouring agent 0.010 g
total dry matter per vial 69.000 g water added 55.000 g suspension volume obtained 100.000 ml suspension content 125 mg clarithromycin /5 ml
Example 2
The process was identical to that of Example 1, only that 1.25 kg of clarithromycin, 1.25 kg of stearic acid and 1.5 kg of NaH2P04 were homogeneously mixed.
Dry additives per vial or per 7.2 g of clarithromycin-coated granulate (pellets):
NaCl 1.000 g aspartame 0.100 g aerosil 0.400 g caramel flavour 0.070 g erytritol 0.140 g maltitol 60.690 g methyl hydroxybenzoate 0.260 g titanium dioxide 0.050 g quinoline yellow colouring agent 0.010 g citric acid 0.010 g
Example 3
The preparation of the granulate was identical to that of Examples 1 or 2. Additionally, a gastroresistant coating was applied; for 200 mg of pellet cores the following dispersion was prepared:
HPMC phthalate 55 48.612 mg dibutyl sebacate 0.893 mg talc 0.495 mg ethanol 332.143 mg acetone 332.143 mg
If a gastroresistant coating was applied, the amount of the sweetening agent was reduced for 50 mg; otherwise the preparation of the final suspension was identical to the one of Example 1.
Example 4
The preparation of the granulate was identical to the one of Examples 1 or 2. Additionally, a gastroresistant coating was applied; for 500 mg of pellet cores the following water dispersion was prepared: Eudragit L 30 D-55 48.612 mg triethyl citrate 0.893 mg talc 0.495 mg water 332.143 mg
The preparation of the water dispersion: triethyl citrate, talc and the antifoaming agent were dispersed in water and homogenized. Immediately before use, it was added under stirring into the Eudragit dispersion and filtered.

Claims

Claims
1. Pharmaceutical formulation in the form of a granulate for oral use, characterized in that it contains clarithromycin or its derivatives coated with a lipid substance.
2. Pharmaceutical formulation according to claim 1, characterized in that clarithromycin or its derivative is admixed with other pharmaceutically acceptable additives.
3. Pharmaceutical formulation according to claim 2, characterized in that the pharmaceutically acceptable additive is a polymer insoluble in stomach.
4. Pharmaceutical formulation according to claim 3, characterized in that the polymer insoluble in stomach is a copolymer of methacrylic acid and methyl methacrylate.
5. Pharmaceutical formulation according to claim 1, characterized in that the lipid substance is a higher fatty alcohol or a suitable acid or a mixture thereof.
6. Pharmaceutical formulation according to claim 1, characterized in that it is, by the addition of other pharmaceutically acceptable substances, prepared in the form of tablets or capsules.
7. Pharmaceutical formulation according to claim 1, characterized in that it is, by the addition of other pharmaceutically acceptable substances, prepared in the form of a suspension.
8. Pharmaceutical formulation according to claim 7, characterized in that it is prepared without sugar (saccharose).
9. Pharmaceutical formulation according to claim 7, characterized in that polyols are added as sweetening agents.
10. Pharmaceutical formulation according to any of claims 1 to 6, characterized in that, additionally, a gastroresistant coating is applied.
11. A process for the preparation of a pharmaceutical formulation according to claim 1, characterized in that it comprises a homogeneous mixing of a coating mixture, melt granulation, cooling and an addition of other excipients for the formation of a granulate.
12. A process for the preparation of a pharmaceutical formulation according to claim 11, characterized in that it is completed by applying a gastroresistant coating.
13. Pharmaceutical formulation in granulate form for oral use, characterized in that it is prepared according to the process of claim 11.
14. Pharmaceutical formulation according to claim 1 useful for the treatment and prophylaxis of bacterial infections.
EP00931886A 1999-05-19 2000-05-18 Melt granulation Withdrawn EP1183013A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI9900119A SI20244A (en) 1999-05-19 1999-05-19 Melt granulation
SI9900119 1999-05-19
PCT/SI2000/000013 WO2000069415A2 (en) 1999-05-19 2000-05-18 Melt granulation

Publications (1)

Publication Number Publication Date
EP1183013A2 true EP1183013A2 (en) 2002-03-06

Family

ID=20432471

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931886A Withdrawn EP1183013A2 (en) 1999-05-19 2000-05-18 Melt granulation

Country Status (13)

Country Link
EP (1) EP1183013A2 (en)
AU (1) AU4969700A (en)
BG (1) BG106236A (en)
CZ (1) CZ20014133A3 (en)
EE (1) EE200100607A (en)
HR (1) HRP20010932A2 (en)
HU (1) HUP0201233A3 (en)
PL (1) PL351654A1 (en)
RU (1) RU2001134166A (en)
SI (1) SI20244A (en)
SK (1) SK16642001A3 (en)
WO (1) WO2000069415A2 (en)
YU (1) YU82001A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1267840T3 (en) * 2000-03-28 2009-09-07 Sandoz Ag Granulated particles with masked taste
MXPA03003146A (en) * 2000-10-13 2004-12-06 Advancis Pharmaceuticals Extended release erythromycin derivatives.
AU2003211243B8 (en) 2002-02-21 2008-11-06 Otsuka Pharmaceutical Co., Ltd. Sustained release preparations and process for producing the same
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
JP3265680B2 (en) * 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
EP0670716B1 (en) * 1992-11-30 2003-03-26 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
IT1312058B1 (en) * 1999-04-09 2002-04-04 Pharmaplus S R L METHOD FOR MICRO-ENCAPSULATION OF MEDICATIONS.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0069415A2 *

Also Published As

Publication number Publication date
WO2000069415A2 (en) 2000-11-23
SI20244A (en) 2000-12-31
EE200100607A (en) 2003-02-17
SK16642001A3 (en) 2002-05-09
HUP0201233A3 (en) 2003-10-28
YU82001A (en) 2004-07-15
CZ20014133A3 (en) 2002-03-13
BG106236A (en) 2002-08-30
AU4969700A (en) 2000-12-05
WO2000069415A3 (en) 2001-04-26
HRP20010932A2 (en) 2003-04-30
RU2001134166A (en) 2003-08-27
PL351654A1 (en) 2003-05-19
HUP0201233A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
JP3470198B2 (en) Composition for oral administration
RU2403015C2 (en) Gastroresistant pharmaceutical compositions containing rifaximin
JP4346817B2 (en) Oral preparation
US5707646A (en) Taste masking pharmaceutical composition
EP2258351B1 (en) Granules containing lansoprazole in large amount
US20070148235A1 (en) Pharmaceutical composition
EP1194153B1 (en) Taste masked pharmaceutical liquid formulations
JP4740740B2 (en) Drug-containing particles and solid preparation containing the particles
US8147874B2 (en) Coated pellets
RU2241460C2 (en) Cefuroxime axetyl-containing pharmaceutical composition with masked bitter taste
EP1267840B1 (en) Granulated particles with masked taste
JP2000103730A (en) Medicine composition having improved feeling of administration
CZ20014379A3 (en) Composition for masking taste and process for preparing thereof
JP2973751B2 (en) Method for producing flavored oral composition
WO2000069415A2 (en) Melt granulation
US20210077451A1 (en) A stable oral pharmaceutical composition of ferric citrate
WO2004096175A2 (en) Taste masked microcapsules and processes for their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20011218;LV PAYMENT 20011218;MK PAYMENT 20011218;RO PAYMENT 20011218;SI PAYMENT 20011218

17Q First examination report despatched

Effective date: 20030811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050210